Defining medical necessity in an age of personalised medicine: A view from Canada

BioEssays

Volumn 36, Issue 9, 2014, Pages 813-817

  Caulfield, Timothy ^a   Zarzeczny, Amy ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF REGINA   (Canada)

Author keywords

Access; Healthcare; Medical necessity; Medically necessary; Medically required; Personalized medicine; Professional obligations

Indexed keywords

ARTICLE; CANADA; FUNDING; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; LEGAL ASPECT; MEDICAL ETHICS; PERSONALIZED MEDICINE; PHYSICIAN; ETHICS; LEGISLATION AND JURISPRUDENCE; PATIENT CARE; PATIENT RIGHT;

CANADA; ETHICS, MEDICAL; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT CARE; PATIENT RIGHTS;

EID: 84905917045     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201400073     Document Type: Article

References (29)

1. Collins F. 2005. Personalized Medicine: How the Human Genome Era Will Usher in a Health Care Revolution. Personalized Medicine Coalition, 10 February 2005. National Institutes of Health, National Human Genome Research Institute Website: http://www.genome.gov/13514107 (accessed 7 April 2014).
2. Hamburg M, Collins F. 2010. The path to personalized medicine. New Engl J Med 363: 301-4.
3. For example, Genome Canada: http://www.genomecanada.ca/en/
4. Canadian Institutes of Health Research (News Release). 2012. Harper Government Invests in Personalized Medicine. June 2012. http://www.cihr-irsc.gc.ca/e/44825.html (accessed 21 April 2014).
5. Mirnezami R, Nicholson J, Darzi A. 2012. Preparing for precision medicine. New Engl J Med 366: 489-91.
6. Juengst E, Flatt M, Settersten R. 2012. Personalized genomic medicine and the rhetoric of empowerment. Hastings Cent Rep 42: 34-40.
7. National Institutes of Health. 2014. Genetics Home Reference. http://ghr.nlm.nih.gov/glossary=personalizedmedicine (accessed 21 April 2014).
8. Simmons L, Dinan M, Robinson T, Snyderman R. 2012. Personalized medicine is more than genomic medicine: confusion over terminology impedes progress towards personalized healthcare. Pers Med 9: 85-91.
9. Hu S, Aitken M, Epstein A, Trusheim M, et al. 2013. Defining and quantifying the use of personalized medicines. Nat Rev Drug Discov 12: 896-7.
10. Jones J. 2009. Francis Collins Addresses State of Personalized Medicine. GenomeWeb Daily News 30 January 2009: http://www.genomeweb.com/dxpgx/francis-collins-addresses-state-personalized-medicine (accessed 21 April 2014).
11. Kimmel SE, French B, Kasner SE, Johnson J, et al. 2013. A pharmacogenetic versus a clinical algorithm for warfarin dosing. New Engl J Med 369: 2283-93.
12. Winslow R. 2012. The future of medicine is now. Wall Street J 31 December 2012: http://online.wsj.com/news/articles/SB10001424127887323530404578205692226506324?mg=reno64-wsj&url=http%3A%2F%2Fonline.wsj.com%2Farticle%2FSB10001424127887323530404578205692226506324.html (accessed 21 April 2014).
13. Caulfield T, Evans J, McGuire A, McCabe C, et al. 2013. Reflections on the cost of "low- cost" whole genome sequencing: framing the health policy debate. PLoS Biol 11: e1001699.
14. Dewey FE, Grove ME, Pan C, Goldstein BA, et al. 2014. Clinical interpretation and implications of whole- genome sequencing. J Am Med Assoc 311: 1035-45.
15. Flores M, Glusman G, Brogaard K, Price N, et al. 2013. P4 medicine: how systems medicine will transform the healthcare sector and society. Pers Med 10: 565-76.
16. Crockford A, Jamal-Hanjani M, Swanton C. 2014. Implications of intratumour heterogeneity for treatment stratification. J Pathol 232: 264-73.
17. Jeison M, Yaniv I, Ash S. 2011. Genetic stratification of neuroblastoma for treatment tailoring. Future Oncol 7: 1087-99.
18. Zenz T, Döhner H, Stilgenbauer S. 2007. Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. Best Pract Res Cl Ha 20: 439-53.
19. Phillips K, Sakowski J, Trosman J, Douglas M, et al. 2014. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med 16: 251-7.
20. Long T. 2013. Essential contractual language for medical necessity in children. Pediatrics 132: 398-401.
21. Skinner D. 2013. Defining medical necessity under the patient protection and affordable care act. Public Admin Rev 73: S49-59.
22. Hill BJ. 2012. What is the meaning of health - constitutional implications of defining medical necessity and essential health benefits under the affordable care act. Am J Law Med 38: 445-70.
23. Caulfield T. 1996. Wishful thinking: defining 'medically necessary' in Canada. Health Law J 4: 63-85.
24. Commission on the Future of Health Care in Canada. 2002. Issue/Survey Paper - Medically Necessary: What is it, and who decides? Available at: http://www.cfhi-fcass.ca/Libraries/Romonow_Commission_ENGLISH/Discussion_Paper_Medically_necessary_What_is_and_who_decides.sflb.ashx (accessed 21 April 2014).
25. Herbert E, Kneebone R. 2013. The challenge of defining Medicare coverage in Canada. SPP Res Papers Online Resour 6: 23p.
26. Caulfield T, 2002. How Do Current Common Law Principles Impede or Facilitate Change? In: Commission on the Future of Health Care in Canada, Discussion Paper 24. Available at: http://publications.gc.ca/collections/Collection/CP32-79-24-2002E.pdf (accessed 21 April 2014).
27. Attaran A. 2009. Take your medicine? The risk of patient-led litigation in Canada's medicine access system. McGill J Law Med 3: 4-20.
28. For example, see: http://www.choosingwisely.org and http://www.choosingwiselycanada.org/ (accessed 21 April 2014).
29. U.S. Department of Health and Human Services, Food and Drug Administration. 2013. Paving the Way for Personalized Medicine; FDA's Role in a New Era of Medical Product Development. Available at: http://www.fda.gov/downloads/scienceresearch/specialtopics/personalizedmedicine/ucm372421.pdf (accessed 21 April 2014).